Eribulin is effective in pretreated advanced breast cancer patients

Eribulin in Metastatic Breast CancerПодробнее

Eribulin as Treatment for Metastatic Breast CancerПодробнее

Eribulin in Recurrent Metastatic ER+ Breast CancerПодробнее

Eribulin’s Role in Triple-Negative Breast CancerПодробнее

Patient Selection for Eribulin in Breast CancerПодробнее

Dr. Vahdat on Capecitabine and Eribulin in Advanced Breast CancerПодробнее

Treatment With Eribulin in Metastatic Breast CancerПодробнее

Dr. Joyce O'Shaughnessy on Eribulin in Metastatic Breast CancerПодробнее

Dr. William Gradishar Discusses the Eribulin and Capecitabine 301 StudyПодробнее

Dr. Twelves Discusses Eribulin for the Treatment of Breast CancerПодробнее

Treatment With Eribulin Mesylate in Metastatic Breast CancerПодробнее

HER2CLIMB: tucatinib efficacious against brain metastases in patients with HER2+ breast cancerПодробнее

Joyce O’Shaughnessy, MD: Candidacy for Eribulin TherapyПодробнее

Joyce O’Shaughnessy, MD: Candidacy for Eribulin TherapyПодробнее

Andrew Seidman, MD: Main Indications for Dose Reduction With EribulinПодробнее

Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant studyПодробнее

Survival Outcomes With Balixafortide Plus Eribulin for Patients With HER2-Metastatic Breast CancerПодробнее

Dr. Chris Twelves Compares Eribulin and CapecitabineПодробнее

Eribulin in Metastatic TNBC: Real-World DataПодробнее